RTP Mobile Logo

Friday, December 6, 2024, San Diego, California, 7:30 AM – 9:30 AM PT (10:30 AM – 12:30 PM ET)

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia

A CME Friday Satellite Symposium and Webcast Preceding the 66th ASH Annual Meeting

Event Details

Program Schedule — Pacific Time
7:00 AM – 7:30 AM — Registration and Breakfast
7:30 AM – 9:30 AM — Educational Meeting

Location
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, California

Meeting Room
Seaport E-H (Second Level)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Diego, preregistration is required as seating is limited.  
 
Faculty
Farrukh T Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C Simmons Comprehensive Cancer Center
The University of Texas
Southwestern Medical Center
Dallas, Texas

Bita Fakhri, MD, MPH
Assistant Professor of Medicine (Hematology)
Stanford University School of Medicine
Stanford, California

Kerry A Rogers, MD
Associate Professor
Division of Hematology
The Ohio State University
Columbus, Ohio


William G Wierda, MD, PhD
Jane and John Justin Distinguished Chair
in Leukemia Research in Honor of Dr Elihu Estey
Section Chief, Chronic Lymphocytic Leukemia
Center Medical Director
Department of Leukemia
Division of Cancer Medicine
Executive Medical Director
Inpatient Medical Services
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator
Jeff Sharman, MD
Medical Director of Hematology Research
US Oncology/Sarah Cannon Research Institute
Willamette Valley Cancer Center
Eugene, Oregon



This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, and Lilly.

Agenda

Program Schedule — Pacific Time
7:00 AM – 7:30 AM — Registration and Breakfast
7:30 AM – 9:30 AM — Educational Meeting

MODULE 1: Optimizing First-Line Therapy for Chronic Lymphocytic Leukemia (CLL)

  • Indications for initiating active therapy for previously untreated CLL; implications of findings from the Phase III CLL12 study
  • Clinical, biological (eg, IGHV mutation, del[17p], TP53 mutation) and practical factors influencing front-line therapeutic selection for patients with CLL requiring treatment
  • Long-term findings from Phase III studies assessing ibrutinib-, acalabrutinib- and zanubrutinib-based therapy for treatment-naïve and relapsed/refractory (R/R) CLL; application in current clinical decision-making
  • Key efficacy and safety data with venetoclax-based up-front treatment for CLL; potential benefits and identification of appropriate patients for time-limited therapy
  • Current and future role of minimal residual disease assessment in clinical decision-making for CLL

MODULE 2: Emerging Role of BTK Inhibitors in Combination with Bcl-2 Inhibitors

  • Mechanistic rationale for combining BTK inhibitors and venetoclax with and without anti-CD20 antibodies for CLL
  • Published datasets evaluating ibrutinib/venetoclax with and without anti-CD20 antibodies for newly diagnosed and R/R CLL
  • Emerging positive findings from the Phase III AMPLIFY trial of fixed-duration acalabrutinib in combination with venetoclax with or without obinutuzumab for previously untreated CLL
  • Available data with zanubrutinib in combination with venetoclax with or without an anti-CD20 antibody
  • Similarities and differences between sonrotoclax and venetoclax; available efficacy and safety findings with sonrotoclax in combination with zanubrutinib for R/R CLL
  • Ongoing Phase III studies assessing novel doublet and triplet combinations of BTK inhibitors with Bcl-2 inhibitors for previously untreated and R/R disease
  • Current role, if any, of BTK/Bcl-2 inhibitor combinations for CLL

MODULE 3: Optimal Management of Adverse Events (AEs) with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations

  • Relevant patient comorbidities (eg, hypertension, preexisting cardiac arrhythmias, chronic kidney disease) and concomitant medications (eg, anticoagulants, proton pump inhibitors) that may influence choice of therapy for CLL
  • Spectrum, frequency and severity of cardiovascular AEs with BTK inhibitors; optimal monitoring and management protocols
  • Incidence and management of noncardiovascular AEs associated with various BTK inhibitors
  • Frequency of tumor lysis syndrome with venetoclax for CLL; monitoring, prophylaxis and management protocols
  • Recommended approaches to identify and manage other common AEs reported with venetoclax (eg, cytopenias, infections, gastrointestinal disorders)
  • Incidence, severity and management of clinically relevant toxicities encountered when combining BTK and Bcl-2 inhibitors with or without anti-CD20 antibodies

MODULE 4: Integration of Noncovalent BTK Inhibitors into the Management of R/R CLL

  • Clinical and biological factors guiding decision-making for patients with R/R CLL; current role of rechallenge with an agent or class of agents received in a prior line of therapy
  • Mechanistic similarities and differences between noncovalent and covalent BTK inhibitors; implications for efficacy and tolerability
  • Antitumor activity documented with pirtobrutinib among patients with R/R CLL, including those with disease progression on covalent BTK inhibitors, in the Phase I/II BRUIN study
  • Spectrum, frequency and severity of toxicities with pirtobrutinib relative to covalent BTK inhibitors
  • FDA approval and current clinical role of pirtobrutinib for R/R CLL
  • Ongoing Phase III trials (eg, BRUIN CLL-313, BRUIN CLL-314, BRUIN CLL-321, BRUIN CLL-322) evaluating pirtobrutinib for CLL
  • Similarities and differences between pirtobrutinib and nemtabrutinib; early efficacy and safety data with nemtabrutinib for R/R CLL and ongoing Phase III evaluation for treatment-naïve disease

MODULE 5: Chimeric Antigen Receptor (CAR) T-Cell Therapy and Other Novel Strategies for CLL

  • Biological rationale for the investigation of CD19-directed CAR T-cell therapy for CLL
  • Published efficacy and safety findings with lisocabtagene maraleucel (liso-cel) for R/R CLL from the Phase I/II TRANSCEND CLL 004 trial
  • FDA approval of liso-cel for CLL previously treated with a BTK inhibitor and a Bcl-2 inhibitor; current clinical role and optimal patient selection
  • Early findings with other CAR T-cell-based approaches (eg, liso-cel in combination with ibrutinib) for heavily pretreated CLL
  • Antitumor activity observed with bispecific antibody therapy for CLL, including in patients with Richter’s transformation
  • Other promising agents and strategies under investigation for CLL

CE Information

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Individualize the selection of systemic therapy for newly diagnosed CLL, considering new research findings, clinical presentation, biomarker profile, coexisting medical conditions and patient preferences for time-limited or continuous treatment.
  • Appraise available Phase III data documenting the comparative efficacy and tolerability of first- and second-generation Bruton tyrosine kinase (BTK) inhibitors, and consider the implications of these findings for clinical decision-making for newly diagnosed CLL.
  • Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented and emerging data documenting the safety and efficacy of this strategy for patients with newly diagnosed CLL.
  • Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with relapsed/refractory (R/R) CLL.
  • Discuss available clinical research findings demonstrating the efficacy and safety of noncovalent BTK inhibitors for CLL, and use this information to effectively incorporate these agents into the care of patients with R/R disease.
  • Evaluate the biological rationale for the investigation of CD19-directed chimeric antigen receptor T-cell therapy for CLL, and identify appropriate patients for this novel therapeutic strategy.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for CLL.
  • Recall available and emerging data with novel agents and combination strategies currently under investigation for CLL, and as applicable, refer eligible patients for clinical trial participation.

CE Credit
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Awan — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Caribou Biosciences Inc, DAVA Oncology, Genmab US Inc, Incyte Corporation, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Contracted Research: Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Boards/Committees: Ascentage Pharma, AstraZeneca Pharmaceuticals LP. Dr Fakhri — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, BeiGene Ltd, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Speakers Bureaus: AbbVie Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company. Dr Rogers — Advisory Committees: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc; Consulting Agreements: AbbVie Inc, Alpine Immune Sciences, BeiGene Ltd, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis. Dr Wierda — Consulting Agreements: BeiGene Ltd, Numab Therapeutics AG; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Bristol Myers Squibb, Cyclacel Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis, Nurix Therapeutics Inc, Oncternal Therapeutics, Pharmacyclics LLC, an AbbVie Company; Nonrelevant Financial Relationships: National Comprehensive Cancer Network (Chair, CLL), Support by the NIH/NCI under award number P30 CA016672 and use of MD Anderson Cancer Center Support Grant (CCSG) shared resources.

MODERATOR — Dr Sharman — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, and Lilly.

Location

Manchester Grand Hyatt San Diego
1 Market Place
San Diego, CA 92101

Meeting Room
Seaport E-H (Second Level)

 

Registration

This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of chronic lymphocytic leukemia.

There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Diego, you must also be registered to attend the ASH 2024 Annual Meeting. Preregistration (below) is required as seating is limited for this program.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.